SHOCKING: Why Is Hantavirus Pulmonary Infection Listed as a Potential Adverse Event in Pfizer’s Early Vaccine Safety Document?

This isn’t a minor footnote. The document, released via FDA FOIA requests (FDA-CBER-2021-5683), contains hundreds of medical conditions Pfizer agreed to monitor closely after the vaccine’s emergency rollout. Critics and independent observers have long questioned the sheer scope of this list and what it implies about the unknowns surrounding the new mRNA technology.

What Is Hantavirus Pulmonary Infection?

Hantavirus Pulmonary Syndrome (HPS) is a rare, often fatal zoonotic disease caused by hantaviruses carried by rodents. Humans typically contract it by inhaling aerosolized particles from rodent droppings, urine, or saliva — not through person-to-person contact in most cases. It starts with flu-like symptoms and can rapidly progress to severe lung inflammation, pulmonary edema, and cardiovascular collapse. Fatality rates can reach 35–40%. It is extremely uncommon, with only dozens of cases reported annually in the U.S., mostly in rural western states.

So why is a rodent-borne virus from the American Southwest (or similar global strains) appearing on a list of monitored adverse events for a COVID-19 vaccine administered worldwide?

Hantavirus is listed in Pfizer’s 38-page document.
Page 33. It’s one of 1,233 listed side effects.

So now the COVID vaccine is going to transform into a virus? pic.twitter.com/VVanLq5Y8B

— Mr. Whale (@CryptoWhale) May 7, 2026

As a reminder: Pfizer released the full documentation on vaccine side effects only after a court order - more than 2 years after the start of mass vaccinations. Previously, the FDA (at Pfizer’s request) had proposed a release schedule that would have taken 55–75 years. pic.twitter.com/QuKX0ZyHAN

— Mr. Whale (@CryptoWhale) May 7, 2026

Official Explanation vs. Lingering Questions

Pfizer and regulators state that the AESI list was compiled from sources like the Brighton Collaboration’s SPEAC project, CDC preliminary lists, MHRA guidelines, and others. It includes:

• Events known or suspected from COVID-19 disease itself.


• Conditions associated with vaccines in general.


• Theoretical risks based on platform or immunopathogenesis.

The list is described as a proactive monitoring tool — not proven side effects — to flag anything reported at higher-than-expected rates for further investigation.

Skeptics ask: Why cast such an absurdly wide net? Hantavirus has no established connection to vaccines, mRNA technology, or spike protein mechanisms. It’s not a common mimic of vaccine reactions in the way, say, Guillain-Barré or myocarditis might be. Its inclusion alongside hundreds of other disparate conditions (epilepsies, hepatic thromboses, various herpes reactivations, autoimmune disorders, etc.) raises eyebrows. Was this list padded to create plausible deniability — so that almost any severe respiratory or multi-system failure post-vaccination could be attributed to “background” or coincidental events rather than the shot?

In spontaneous reporting systems like VAERS, events are reported regardless of proven causality. By pre-listing something as exotic as hantavirus, authorities could later dismiss rare severe pulmonary cases as “possibly hantavirus” without deeper scrutiny. Trust in institutions was already strained by the rushed authorization process, changing narratives on transmission, and initial claims of near-perfect safety. Documents like this fuel suspicion: If the vaccine was as safe and straightforward as advertised, why prepare for monitoring an obscure rodent virus?

Broader Context and Reasons for Distrust

By late February 2021, Pfizer had received over 42,000 case reports with nearly 159,000 adverse events. The AESI appendix spans dozens of pages. While defenders argue this reflects thorough pharmacovigilance, critics see it as evidence that manufacturers and regulators anticipated (or at least prepared for) a wide range of serious outcomes.

No large-scale studies have ever established a causal link between BNT162b2 and hantavirus infection — nor would one expect a vaccine to cause a specific zoonotic viral disease. But the listing itself invites questions about immune dysregulation, unexpected reactivations, or diagnostic overlap with vaccine-induced respiratory issues. Why not focus monitoring more narrowly on biologically plausible risks? The expansive approach can make genuine safety signals harder to isolate amid the noise.

This document exemplifies a recurring pattern in the COVID-19 era: official sources provide technically accurate but reassuring framings (“it’s just a monitoring list”), while primary documents reveal a more concerning breadth of tracked harms. Independent researchers, FOIA releases, and persistent public scrutiny have been essential for transparency precisely because trust in centralized authorities eroded.

Readers should examine the full PDF themselves (available on phmpt.org and regulations.gov archives). The presence of “Hantavirus pulmonary infection” may ultimately be bureaucratic overreach — or it may hint at deeper uncertainties about how this novel vaccine interacts with the human body and environment. In an age of eroded institutional credibility, such questions deserve rigorous, independent investigation rather than reflexive dismissal.

Full list of adverse affects of Covid Vaccines:

• fasciitis; eosinophilic granulomatosis with polyangiitis; eosinophilic fasciitis; Epidermolysis; Epilepsy; Epilepsy surgery; Myoclonic-atonic epilepsy; convulsions; epileptic aura; epileptic psychosis; erythema; indurated erythema; erythema multiforme; Erythema nodosum; Evans Syndrome; Sudden exanthema; Expanded disability; decrease in expanded disability status scale score; increase in expanded disability status scale score; exposure to transmissible disease; Exposure to SARS-CoV-2; Ocular edema; Ocular pruritus; swelling; Eyelid edema; Facial edema; Facial paralysis; Facial paresis; Dystonic faciobrachial convulsions; fat embolism; febrile convulsions; epileptic syndrome related to febrile infections; neutropenia; Felty’s syndrome; femoral artery embolism; fibrillary glomerulonephritis; Fibromyalgia; Hot flashes; Foaming at the mouth; Focal cortical resection; Focal discontinuous convulsions; fetal distress syndrome; fetal placental thrombosis; fetus; hepatitis; foreign body embolism; frontal lobe epilepsy; fulminant type 1 diabetes mellitus; Abnormal galactose elimination capacity test; decreased galactose elimination capacity test; abnormal gamma-glutamyltransferase; increased gamma-glutamyltransferase; Herpes gastritis; gastrointestinal Amyloidosis; Galactose convulsion; Generalized onset non-motor seizures; generalized tonic-clonic seizures; genital herpes; genital herpes simplex; Genital herpes zoster; Giant cell arteritis; Glomerulonephritis; membranoproliferative Glomerulonephritis; Membranous glomerulonephritis; Rapidly progressive glomerulonephritis; glossopharyngeal nerve paralysis; glucose transporter type 1 deficiency syndrome; Elevated glutamate dehydrogenase; Elevated glycolic acid; GM2 gangliosidosis; Goodpasture syndrome; graft thrombosis; Granulocytopenia; Neonatal granulocytopenia; Granulomatosis with polyangiitis; Granulomatous dermatitis; Grey matter heterotopia; Increased guanase; Guillain-Barré syndrome; hemolytic Anemia; Hemophagocytic lymphohistiocytosis; Hemorrhage; Hemorrhagic ascites; Hemorrhagic disorder; Hemorrhagic pneumonia; Hemorrhagic varicella syndrome; Hemorrhagic vasculitis; hantavirus pulmonary infection; Hashimoto’s disease encephalopathy; hashitoxicosis; hemimegalencephaly; Henoch-Schonlein purpura; nephritis by Henoch-Schonlein purpura; abnormal hepaplastin; decreased hepaplastin; induced by heparin thrombocytopenia; hepatic amyloidosis; hepatic artery embolism; decreased hepatic artery flow; Hepatic artery thrombosis; Abnormal hepatic enzyme; Hepatic enzyme decrease; increased hepatic enzymes; abnormal hepatic fibrosis marker; increased hepatic fibrosis marker; abnormal hepatic function; hepatic hydrothorax; hypertrophy; hepatic hypoperfusion; hepatic lymphocytic infiltration; hepatic mass; pain; hepatic sequestration; increased hepatic vascular resistance; hepatic vascular resistance thrombosis; Hepatic vein embolism; Hepatic vein thrombosis; abnormal hepatic venous pressure gradient; increased hepatic venous pressure gradient; hepatitis; abnormal hepatobiliary gamma; Hepatomegaly; Hepatosplenomegaly; hereditary Angioedema with C1 esterase inhibitor deficiency; herpes dermatitis; gestational herpes; herpes esophagitis; ophthalmic herpes; herpes pharyngitis; herpes sepsis; herpes simplex; herpes simplex cervicitis; herpes simplex colitis; herpes simplex encephalitis; herpes simplex gastritis; herpes simplex hepatitis; herpes simplex meningitis; herpes simplex meningoencephalitis; necrotizing retinopathy by herpes simplex; herpes simplex esophagitis; herpes simplex otitis externa; herpes simplex pharyngitis; pneumonia; herpes simplex reactivation; herpes simplex sepsis; herpes simplex viremia; neonatal herpes simplex conjunctivitis; visceral herpes simplex; herpes simplex virus.

Source of this document This page comes from Pfizer’s confidential post-authorization safety report titled: “5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162b2) received through 28-FEB-2021” (prepared by Pfizer Worldwide Safety).

It is Appendix 1: LIST OF ADVERSE EVENTS OF SPECIAL INTEREST (starting around page 30–38 of the full PDF). The document was released publicly through FOIA requests to the FDA (file FDA-CBER-2021-5683) and is hosted on sites such as phmpt.org. It compiles hundreds of medical conditions that Pfizer monitored as “Adverse Events of Special Interest” (AESIs) in spontaneous reports received after the vaccine’s emergency authorization/rollout.